RFS Pharma is developing innovative new therapies to treat human diseases. With expertise and initial focus on HIV and hepatitis virus infections, RFS Pharma has development programs in progress for its lead compounds.
RFS Pharma's leading drug candidate, Amdoxovir (DAPD), is currently in advanced Phase II clinical trials.
